Cadila Healthcare Ltd has received tentative approval from the USFDA to market Pravastatin Sodium Tablets in the US market.
Cadila Healthcare Ltd has received tentative approval from the USFDA to market Pravastatin Sodium Tablets in the US market.
The tentative approval was given for strengths of 10 mg, 20 mg, 40 mg and 80 mg, the company informed the Bombay Stock Exchange.The company would market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc, following patent expiry, it added.
The drug, which had branded sales of approximately 1.8 billion dollars in the US market during 2005, is a lipid lowering agent.
Source:PTI News
